Zymeworks Stock Price, News & Analysis

Zymeworks (Nasdaq: ZYME) will present preliminary Phase 1 clinical data for ZW191, an antibody-drug conjugate targeting folate receptor-α using payload ZD06519, at the AACR-NCI-EORTC conference in Boston on October 23, 2025.

The poster covers first-in-human, multicenter, open-label Part 1 results in patients with advanced solid tumors including ovarian, endometrial, and non-small cell lung cancer. A live webcast and investor call with lead author Patricia LoRusso, DO, PhD (hc), FAACR and Zymeworks management will occur on October 23, 2025 at 3:30 pm ET. Dial-in and replay are available on Zymeworks' investor site.

Zymeworks (NASDAQ: ZYME) announced on October 9, 2025 that Adam Schayowitz, Ph.D., MBA, has been appointed Acting Chief Development Officer. He will report to CEO Kenneth Galbraith and work with R&D and Business Development to advance nominated product candidates and integrate partnerships into the wholly‑owned portfolio.

Dr. Schayowitz brings nearly 20 years of oncology drug‑development experience, including leadership roles at Pfizer, Tesaro (Zejula development), and Algeta, and will continue part‑time as an Operating Partner at EcoR1 Capital while serving on boards at Terremoto Biosciences and Aktis Oncology.

The company noted recent milestones including IND clearance for ZW251 and expanded global approvals of zanidatamab.

Zymeworks (Nasdaq: ZYME) has announced the discontinuation of clinical development for ZW171, a T cell engager targeting mesothelin-driven cancers. The decision follows the completion of Phase 1 trial dose escalation cohorts in ovarian cancer and non-small cell lung cancer patients.

While cytokine release syndrome was manageable, the trial revealed dose-limiting toxicities related to mesothelin-targeted effects. The company determined that further dose evaluation would not support a favorable benefit-risk profile. Current trial participants may continue treatment at their investigator's discretion.

Zymeworks continues to advance other pipeline candidates, including the ongoing Phase 1 trial of ZW191, planned Phase 1 study for ZW251 in 2025, and an IND filing for ZW209 in early 2026.

Zymeworks (NASDAQ: ZYME), a clinical-stage biotechnology company, has announced its participation in four major investor conferences in September 2025. The company, which focuses on developing novel biotherapeutics for cancer, inflammation, and autoimmune diseases, will engage in various activities at these events.

Management will attend Citi's Biopharma Back to School Conference (Sept 3), Wells Fargo Healthcare Conference (Sept 4), Cantor Global Healthcare Conference (Sept 5), and Morgan Stanley Annual Global Healthcare Conference (Sept 8). The schedule includes one-on-one meetings at all events and fireside chats at three of the conferences.

Zymeworks (NASDAQ: ZYME), a clinical-stage biotechnology company, has strengthened its Board of Directors with the appointments of Greg Ciongoli and Robert E. Landry, effective August 10, 2025. Both will serve on the Board's audit committee.

Ciongoli, founder of Adiumentum Capital Management, brings extensive healthcare investment and corporate governance experience. Landry contributes over 30 years of financial leadership in pharma and biotech, most recently as CFO at Regeneron Pharmaceuticals.

The appointments come at a crucial time as Zymeworks advances its development programs, including recent regulatory approvals for zanidatamab in the U.S., Europe, and China, and an upcoming HERIZON-GEA-01 topline data readout in Q4 2025. Troy Cox, who served since 2019, has stepped down from the Board.

Zymeworks (NASDAQ:ZYME) reported strong Q2 2025 financial results with $48.7 million in revenue, up from $19.2 million in Q2 2024, and achieved a net income of $2.3 million. The company secured FDA clearance for ZW251's IND application and reported $333.4 million in cash resources as of June 30, 2025.

Key developments include Chinese and European approval for zanidatamab in HER2-positive biliary tract cancer, with Ziihera® generating $5.5 million in net product sales. The company's partner Jazz reported promising long-term data for Ziihera® in gastroesophageal adenocarcinoma, showing median overall survival of 36.5 months. Strategic partnerships with BMS, J&J, and Daiichi Sankyo continue to progress, validating Zymeworks' platform technology.

The company projects cash runway into second half of 2027, supported by milestone payments and partnership revenues.

Zymeworks (NASDAQ:ZYME) announced FDA clearance of its Investigational New Drug (IND) application for ZW251, a novel antibody-drug conjugate (ADC) targeting hepatocellular carcinoma (HCC). ZW251 is designed to target glypican-3 (GPC3), which is expressed in over 75% of HCC cases.

The drug represents Zymeworks' second ADC utilizing their proprietary topoisomerase 1 inhibitor payload. Preclinical studies demonstrated strong anti-tumor activity across various HCC models and favorable tolerability in non-human primates at doses up to 120 mg/kg. The company plans to initiate Phase 1 clinical trials in 2025.

Zymeworks (NASDAQ: ZYME), a clinical-stage biotechnology company, has scheduled its second quarter 2025 financial results announcement for August 7, 2025 after market close. The company will host a conference call and webcast at 4:30 PM ET on the same day to discuss the results and provide a corporate update.

Additionally, Zymeworks' management will participate in two upcoming investor conferences: the BTIG Virtual Biotechnology Conference on July 29 and the Stifel Biotech Summer Summit from August 11-13, featuring one-on-one meetings and fireside chat presentations.

Zymeworks (NASDAQ: ZYME) has received NMPA approval in China for zanidatamab, making it the first dual HER2-targeted bispecific antibody approved for HER2-positive biliary tract cancer in the region. The conditional approval triggers a $20 million milestone payment from BeOne Medicines, with potential for additional $144 million in development and commercial milestones. Zanidatamab was previously approved by the FDA in November 2024 and received positive CHMP opinion in Europe in April 2025. Under the partnership with BeOne Medicines, Zymeworks has already received $61 million in upfront and milestone payments and is eligible for tiered royalties up to 19.5% of net sales in BeOne's territories. The approval represents a significant advancement for patients with HER2-positive BTC, addressing an area of high unmet medical need.